| PATIENT_ID START_DATE STOP_DATE EVENT_TYPE TREATMENT_TYPE TREATMENT_SUBTYPE AGENT NUMBER_OF_CYCLES PRESCRIBED_DOSE PRESCRIBED_DOSE_UNITS REGIMEN_NUMBER REGIMEN_INDICATION REGIMEN_INDICATION_NOTES MEASURE_OF_RESPONSE CLINICAL_TRIAL_DRUG_CLASSIFICATION ROUTE_OF_ADMINISTRATION ROUTE_OF_ADMINISTRATION-2 THERAPY_ONGOING TOTAL_DOSE TOTAL_DOSE_UNITS TX_ON_CLINICAL_TRIAL ANATOMIC_TREATMENT_SITE COURSE_NUMBER NUMBER_OF_FRACTIONS RADIATION_DOSAGE RADIATION_TREATMENT_ONGOING RADIATION_TYPE RADIATION_UNITS PHARM_REGIMEN STEM_CELL_TRANSPLANTATION STEM_CELL_TRANSPLANTATION_TYPE | |
| TCGA-BA-4074 45 97 Treatment Chemotherapy Carboplatin 1 Adjuvant No | |
| TCGA-BA-4074 425 431 Treatment Radiation Therapy Radiation 1 Palliative 2 5 2000 No cgy | |
| TCGA-BA-4074 45 97 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-BA-4076 18 64 Treatment Chemotherapy Fluorouracil 2 1 Adjuvant No | |
| TCGA-BA-4076 18 64 Treatment Chemotherapy Cisplatin 2 1 Adjuvant No | |
| TCGA-BA-4076 18 64 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6800 No cgy | |
| TCGA-BA-4078 51 95 Treatment Radiation Therapy Radiation 1 Adjuvant 1 No | |
| TCGA-BA-5149 59 80 Treatment Chemotherapy Cisplatin 2 100 mg/m2 1 Adjuvant No | |
| TCGA-BA-5149 59 102 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6000 No External Beam cgy | |
| TCGA-BA-5151 55 69 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6600 No External Beam cgy | |
| TCGA-BA-5153 41 91 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No | |
| TCGA-BA-5557 67 109 Treatment Chemotherapy Cisplatin 6 30 mg/m2 1 Adjuvant No | |
| TCGA-BA-5557 67 109 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-BA-5558 78 140 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6480 No External Beam cgy | |
| TCGA-BA-6868 13 48 Treatment Chemotherapy Carboplatin 6 2248 mg 1 Adjuvant IV No 1746 mg | |
| TCGA-BA-6868 13 13 Treatment Chemotherapy Cetuximab 1 692 mg 1 Adjuvant IV No 519 mg | |
| TCGA-BA-6868 69 118 Treatment Chemotherapy Cisplatin 3 540 mg 2 Adjuvant IV No 515 mg | |
| TCGA-BA-6868 14 48 Treatment Chemotherapy Paclitaxel 6 1831 mg 1 Adjuvant IV No 1419 mg | |
| TCGA-BA-6868 70 121 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 35 7000 No External Beam cgy | |
| TCGA-BA-6869 96 137 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-BA-6870 60 152 Treatment Chemotherapy Cisplatin 1 Adjuvant No | |
| TCGA-BA-6870 76 144 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6996 No External Beam cgy | |
| TCGA-BA-6873 72 118 Treatment Chemotherapy Cisplatin 3 100 mg/m2 1 Progression IV No 640 mg | |
| TCGA-BA-6873 72 122 Treatment Radiation Therapy Radiation 1 Progression Local Recurrence 1 4600 No External Beam cgy | |
| TCGA-BA-7269 67 118 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-BA-A4IF 25 53 Treatment Chemotherapy Cisplatin complete response No Yes | |
| TCGA-BA-A4IF 33 75 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 7000 No External cgy | |
| TCGA-BA-A4IG 79 140 Treatment Chemotherapy Cetuximab complete response No No | |
| TCGA-BA-A4IG 86 132 Treatment Radiation Therapy Radiation 1 complete response Regional Site 30 6000 No External cgy | |
| TCGA-BA-A4IH 87 129 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BA-A4IH 88 136 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-BA-A6D8 112 154 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BA-A6D8 107 154 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-BA-A6D8 107 154 Treatment Radiation Therapy Radiation 2 complete response Regional Site 33 5610 No External cgy | |
| TCGA-BA-A6DA 68 110 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BA-A6DA 68 112 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-BA-A6DD 96 163 Treatment Chemotherapy Cisplatin clinical progressive disease No No | |
| TCGA-BA-A6DD 89 133 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 19 3800 No External cgy | |
| TCGA-BA-A6DF 44 92 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 32 6400 No External cgy | |
| TCGA-BA-A6DG 58 61 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 2 400 No External cgy | |
| TCGA-BA-A6DI 18 53 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BA-A6DI 18 62 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 32 6400 No External cgy | |
| TCGA-BA-A6DJ 105 140 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BA-A6DJ 104 160 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-BA-A6DJ 104 160 Treatment Radiation Therapy Radiation 2 complete response Regional Site 30 6000 No External cgy | |
| TCGA-BA-A6DL 21 56 Treatment Chemotherapy Carboplatin complete response No Yes | |
| TCGA-BA-A6DL 21 56 Treatment Chemotherapy Paclitaxel complete response No Yes | |
| TCGA-BA-A6DL 21 56 Treatment Chemotherapy Lapatinib complete response No Yes | |
| TCGA-BA-A8YP 39 100 Treatment Chemotherapy complete response No No | |
| TCGA-BA-A8YP 49 102 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 31 6200 No External cgy | |
| TCGA-BB-4217 115 121 Treatment Radiation Therapy Radiation 1 Adjuvant 1 No | |
| TCGA-BB-4223 98 140 Treatment Chemotherapy Cisplatin 6 100 mg/m2 1 Adjuvant IV No 600 mg/m2 | |
| TCGA-BB-4223 94 135 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 6000 No External Beam cgy | |
| TCGA-BB-4223 136 140 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 2 600 No External Beam cgy | |
| TCGA-BB-4224 182 202 Treatment Chemotherapy Cisplatin 2 75 mg/m2 1 Palliative IV No 150 mg/m2 | |
| TCGA-BB-4224 229 243 Treatment Chemotherapy Gemcitabine 2 mg/m2 2 Palliative IV No mg/m2 | |
| TCGA-BB-4224 2786 2799 Treatment Chemotherapy Oxaliplatin 2 mg/m2 2 Palliative IV No mg/m2 | |
| TCGA-BB-4224 182 202 Treatment Chemotherapy Docetaxel 2 75 mg/m2 1 Palliative IV No 150 mg/m2 | |
| TCGA-BB-4224 30 69 Treatment Radiation Therapy Radiation 1 Regional Site 5580 No External Beam cgy | |
| TCGA-BB-4228 26 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 1 600 No cgy | |
| TCGA-BB-7861 43 71 Treatment Chemotherapy complete response No No | |
| TCGA-BB-7861 43 71 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-BB-7862 92 145 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-BB-7864 136 179 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BB-7864 136 179 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000.00 No External cgy | |
| TCGA-BB-7866 71 116 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BB-7866 70 116 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 7000.00 No External gy | |
| TCGA-BB-7870 64 119 Treatment Radiation Therapy Radiation 1 complete response 6000 No cgy | |
| TCGA-BB-7871 143 185 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-BB-7872 112 154 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BB-7872 112 154 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6600.00 No External cgy | |
| TCGA-BB-A5HU 69 97 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BB-A5HU 68 110 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6600.00 No External cgy | |
| TCGA-BB-A5HY 84 121 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-BB-A5HY 83 127 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 182 No External gy | |
| TCGA-BB-A5HY 275 281 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Distant Recurrence 5 2500 No External cgy | |
| TCGA-BB-A5HZ 94 136 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6300 No External cgy | |
| TCGA-BB-A6UM 150 181 Treatment Chemotherapy complete response No No | |
| TCGA-BB-A6UM 150 181 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-BB-A6UO 105 150 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6600 No External cgy | |
| TCGA-CN-4726 90 94 Treatment Chemotherapy Cisplatin 1 100 mg/m2/wk 1 Recurrence IV No | |
| TCGA-CN-4726 90 94 Treatment Radiation Therapy Radiation 1 Recurrence Regional Site 2 5 1100 No External Beam cgy | |
| TCGA-CN-4727 83 143 Treatment Chemotherapy Cisplatin mg/m2/wk 1 Adjuvant IV No mg/m2/wk | |
| TCGA-CN-4727 94 143 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No External Beam cgy | |
| TCGA-CN-4728 44 87 Treatment Chemotherapy Panitumumab 7 2.5 mg/kg 1 Adjuvant IV No mg/kg | |
| TCGA-CN-4728 44 87 Treatment Chemotherapy Cisplatin 7 30 mg/m2/wk 1 Adjuvant IV No | |
| TCGA-CN-4728 44 87 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-4731 273 301 Treatment Chemotherapy Cetuximab mg/m2/wk 1 Recurrence IV No mg/m2/wk | |
| TCGA-CN-4731 546 560 Treatment Chemotherapy Cetuximab 3 100 mg/ml 1 Recurrence IV No 300 mg/ml | |
| TCGA-CN-4731 827 869 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-CN-4731 937 958 Treatment Chemotherapy Docetaxel clinical progressive disease No Yes | |
| TCGA-CN-4731 273 323 Treatment Radiation Therapy Radiation 1 Recurrence Local Recurrence 2 35 7000 No External Beam cgy | |
| TCGA-CN-4731 538 562 Treatment Radiation Therapy Radiation 2 Recurrence Regional Site 3 5 4400 No Other cgy | |
| TCGA-CN-4734 73 115 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 5400 No External Beam cgy | |
| TCGA-CN-4735 46 88 Treatment Chemotherapy Panitumumab 2.5 mg/kg 1 Adjuvant IV No | |
| TCGA-CN-4735 46 88 Treatment Chemotherapy Cisplatin 3 30 mg/m2/wk 1 Adjuvant IV No | |
| TCGA-CN-4735 46 88 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-4736 262 322 Treatment Chemotherapy Cisplatin mg/m2 1 Recurrence IV No mg/m2 | |
| TCGA-CN-4736 269 322 Treatment Radiation Therapy Radiation 1 Recurrence Regional Site 2 35 7000 No External Beam cgy | |
| TCGA-CN-4737 43 85 Treatment Chemotherapy Cisplatin mg/ml 1 Adjuvant IV No 50 mg/ml | |
| TCGA-CN-4737 43 85 Treatment Chemotherapy Panitumumab mg/ml 1 Adjuvant IV No 100 mg/ml | |
| TCGA-CN-4737 43 85 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-4738 251 280 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 3200 No External Beam cgy | |
| TCGA-CN-4739 115 161 Treatment Chemotherapy Carboplatin auc Adjuvant IV No auc | |
| TCGA-CN-4739 115 161 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 31 6200 No External Beam cgy | |
| TCGA-CN-4740 260 276 Treatment Chemotherapy Cetuximab mg/ml 1 Recurrence IV No mg/ml | |
| TCGA-CN-4740 757 791 Treatment Chemotherapy Everolimus 1 mg/ml 1 Recurrence IV No mg/ml | |
| TCGA-CN-4740 266 276 Treatment Radiation Therapy Radiation 1 Recurrence Regional Site 2 5 4400 No Other cgy | |
| TCGA-CN-4740 98 160 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 1 36 6480 No External Beam cgy | |
| TCGA-CN-4741 103 163 Treatment Chemotherapy Cisplatin mg 1 Adjuvant IV No mg | |
| TCGA-CN-4741 1771 1778 Treatment Immunotherapy Cetuximab complete response No No | |
| TCGA-CN-4741 103 163 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6600 No External Beam cgy | |
| TCGA-CN-4741 1771 1780 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5 4400 No External cgy | |
| TCGA-CN-4742 168 237 Treatment Chemotherapy Cisplatin auc Adjuvant IV No auc | |
| TCGA-CN-4742 165 237 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 41 7380 No External Beam cgy | |
| TCGA-CN-5358 223 Treatment Chemotherapy Carboplatin auc 2 Recurrence IV Yes auc | |
| TCGA-CN-5358 202 Treatment Chemotherapy Cisplatin auc 1 Recurrence IV Yes auc | |
| TCGA-CN-5358 202 Treatment Radiation Therapy Radiation 1 Recurrence Regional Site 2 Yes External Beam cgy | |
| TCGA-CN-5359 54 79 Treatment Chemotherapy Cisplatin 10 mg/ml 1 Adjuvant IV No 80 mg/ml | |
| TCGA-CN-5359 54 79 Treatment Chemotherapy Panitumumab 20 mg/ml 1 Adjuvant IV No 160 mg/ml | |
| TCGA-CN-5359 53 96 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-5360 80 125 Treatment Chemotherapy Cisplatin 3 mg 1 Adjuvant IV No mg | |
| TCGA-CN-5360 80 122 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-5364 231 303 Treatment Chemotherapy Carboplatin mg 1 Adjuvant IV No mg | |
| TCGA-CN-5364 231 303 Treatment Chemotherapy Paclitaxel mg 1 Adjuvant IV No mg | |
| TCGA-CN-5364 231 289 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 35 6640 No External Beam cgy | |
| TCGA-CN-5366 86 147 Treatment Chemotherapy mg 1 Adjuvant IV No mg | |
| TCGA-CN-5366 94 151 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 5500 No External Beam cgy | |
| TCGA-CN-5367 88 139 Treatment Chemotherapy Cisplatin mg 1 Adjuvant IV No mg | |
| TCGA-CN-5367 83 139 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6000 No External Beam cgy | |
| TCGA-CN-5370 142 183 Treatment Chemotherapy Cisplatin 3 mg/ml 1 Recurrence IV No mg/ml | |
| TCGA-CN-5370 142 183 Treatment Chemotherapy Cisplatin 3 mg/ml 3 Recurrence IV No mg/ml | |
| TCGA-CN-5370 142 183 Treatment Chemotherapy Cisplatin 3 mg/ml 2 Recurrence IV No mg/ml | |
| TCGA-CN-5370 144 199 Treatment Radiation Therapy Radiation 1 Recurrence Primary Tumor Field 2 34 6800 No External Beam cgy | |
| TCGA-CN-5373 66 109 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-5374 112 182 Treatment Chemotherapy Cisplatin mg 1 Adjuvant INTRAVESICAL No mg | |
| TCGA-CN-5374 116 187 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 34 7200 No External Beam cgy | |
| TCGA-CN-6010 50 70 Treatment Chemotherapy Cisplatin 2 10 mg/ml 1 Adjuvant IV No 10 mg/ml | |
| TCGA-CN-6010 47 98 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-6011 109 159 Treatment Chemotherapy Cisplatin mg/ml 1 Adjuvant IV No mg/ml | |
| TCGA-CN-6011 102 157 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CN-6012 157 200 Treatment Chemotherapy Cisplatin mg/ml 1 Adjuvant IV No mg/ml | |
| TCGA-CN-6012 157 207 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No External Beam cgy | |
| TCGA-CN-6013 103 148 Treatment Chemotherapy Cisplatin 3 100 mg/m2 1 Adjuvant IV No 100 mg/m2 | |
| TCGA-CN-6013 103 148 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CN-6016 92 141 Treatment Chemotherapy Carboplatin 2 auc 1 Adjuvant IV No 2 auc | |
| TCGA-CN-6016 93 156 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 39 7020 No External Beam cgy | |
| TCGA-CN-6017 103 110 Treatment Chemotherapy Carboplatin 50 mg/ml 1 Adjuvant IV No 50 mg/ml | |
| TCGA-CN-6017 75 96 Treatment Chemotherapy Cisplatin 10 mg/ml 1 Adjuvant IV No 10 mg/ml | |
| TCGA-CN-6017 75 117 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CN-6019 56 84 Treatment Chemotherapy Cisplatin 10 mg/ml 1 Adjuvant IV No 10 mg/ml | |
| TCGA-CN-6019 56 91 Treatment Chemotherapy Panitumumab 20 mg/ml 1 Adjuvant IV No 20 mg/ml | |
| TCGA-CN-6019 56 97 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-6020 101 140 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CN-6022 166 185 Treatment Radiation Therapy Radiation 1 Progression Regional Site 2 10 1800 No External Beam cgy | |
| TCGA-CN-6023 49 99 Treatment Chemotherapy Cetuximab mg/ml 1 Adjuvant IV No mg/ml | |
| TCGA-CN-6023 49 99 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 35 6300 No External Beam cgy | |
| TCGA-CN-6989 73 114 Treatment Chemotherapy Carboplatin 4 50 mg/ml 1 Adjuvant IV No 200 mg/ml | |
| TCGA-CN-6989 791 855 Treatment Chemotherapy Gemcitabine clinical progressive disease No No | |
| TCGA-CN-6989 889 917 Treatment Chemotherapy Methotrexate clinical progressive disease No No | |
| TCGA-CN-6989 72 116 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 32 6400 No External Beam cgy | |
| TCGA-CN-6992 71 Treatment Chemotherapy Cisplatin 3 10 mg/ml 1 Adjuvant IV Yes 30 mg/ml | |
| TCGA-CN-6992 70 140 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CN-6996 70 Treatment Chemotherapy Cisplatin 3 10 mg/ml 1 Adjuvant IV Yes 30 mg/ml | |
| TCGA-CN-6996 378 378 Treatment Targeted Molecular Therapy Capecitabine clinical progressive disease No Yes | |
| TCGA-CN-6996 378 378 Treatment Targeted Molecular Therapy Vorinostat clinical progressive disease No Yes | |
| TCGA-CN-6996 418 Treatment Vaccine Vaccine Nos clinical progressive disease Yes Yes | |
| TCGA-CN-6996 71 119 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CN-6997 59 101 Treatment Chemotherapy Cisplatin 3 mg/ml 1 Adjuvant IV No mg/ml | |
| TCGA-CN-6997 363 Treatment Chemotherapy Cetuximab Yes No | |
| TCGA-CN-6997 70 113 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6600 No External Beam cgy | |
| TCGA-CN-6998 64 131 Treatment Chemotherapy Cisplatin clinical progressive disease No No | |
| TCGA-CN-6998 63 141 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 38 6840 No External cgy | |
| TCGA-CN-A498 59 101 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CN-A498 480 487 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-CN-A498 674 723 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-CN-A498 744 751 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-CN-A498 744 751 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-CN-A498 51 107 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 6440 No External cgy | |
| TCGA-CN-A498 480 493 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Regional Site 5 44 No External gy | |
| TCGA-CN-A49A 76 126 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CN-A49A 76 128 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6600 No External cgy | |
| TCGA-CN-A49A 365 365 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Distant Recurrence 1 1500 No External cgy | |
| TCGA-CN-A49B 161 213 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6600 No External cgy | |
| TCGA-CN-A49C 26 78 Treatment Chemotherapy Cetuximab complete response No No | |
| TCGA-CN-A49C 26 78 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 34 7300 No External cgy | |
| TCGA-CN-A63T 64 64 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-CN-A63T 64 72 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 5 9 No External gy | |
| TCGA-CN-A63U 36 86 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 60 No External gy | |
| TCGA-CN-A63W 69 138 Treatment Chemotherapy Panitumumab complete response No Yes | |
| TCGA-CN-A63W 69 138 Treatment Chemotherapy Cisplatin complete response No Yes | |
| TCGA-CN-A63W 69 138 Treatment Chemotherapy Carboplatin complete response No Yes | |
| TCGA-CN-A63W 69 145 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-CN-A641 187 239 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-CN-A641 185 239 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CN-A6UY 59 106 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CN-A6UY 59 101 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6900 No External cgy | |
| TCGA-CN-A6V1 13 34 Treatment Immunotherapy Cetuximab complete response No Yes | |
| TCGA-CN-A6V3 130 151 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-CN-A6V3 130 178 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CN-A6V6 74 116 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-CN-A6V6 74 119 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CN-A6V7 83 104 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-CN-A6V7 83 132 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 7000 No External cgy | |
| TCGA-CQ-5323 47 83 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 25 5000 No External Beam cgy | |
| TCGA-CQ-5325 244 276 Treatment Radiation Therapy Radiation 1 Recurrence Primary Tumor Field 1 25 6000 No External Beam cgy | |
| TCGA-CQ-5326 64 73 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 8 1696 No External Beam cgy | |
| TCGA-CQ-5327 57 57 Treatment Chemotherapy Cisplatin 1 150 mg 1 Adjuvant IV No 150 mg | |
| TCGA-CQ-5327 54 99 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CQ-5330 57 88 Treatment Chemotherapy 1 Adjuvant IV No | |
| TCGA-CQ-5330 57 88 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CQ-5333 223 244 Treatment Radiation Therapy Radiation 1 Palliative Primary Tumor Field 1 3 2400 No External Beam cgy | |
| TCGA-CQ-5334 55 69 Treatment Radiation Therapy Radiation 1 Palliative Primary Tumor Field 1 10 2508 No External Beam cgy | |
| TCGA-CQ-6218 90 121 Treatment Chemotherapy Cisplatin 2 260 mg 1 Adjuvant IV No 260 mg | |
| TCGA-CQ-6218 90 129 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CQ-6219 286 324 Treatment Radiation Therapy Radiation 1 Recurrence Local Recurrence 1 35 7000 No External Beam cgy | |
| TCGA-CQ-6224 61 81 Treatment Chemotherapy Cisplatin 2 170 mg 1 Adjuvant IV No 340 mg | |
| TCGA-CQ-6224 61 103 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CQ-6225 49 91 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 18 4320 No External Beam cgy | |
| TCGA-CQ-6228 315 319 Treatment Radiation Therapy Radiation 1 Recurrence Distant Recurrence 2 5 2000 No External Beam cgy | |
| TCGA-CQ-6228 154 186 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 1 25 6000 No External Beam cgy | |
| TCGA-CQ-7064 116 162 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CQ-7065 249 291 Treatment Chemotherapy Cisplatin 3 197 mg 1 Recurrence IV No 477 mg | |
| TCGA-CQ-7065 248 294 Treatment Radiation Therapy Radiation 1 Recurrence Primary Tumor Field 1 35 7000 No External Beam cgy | |
| TCGA-CQ-7068 1248 1302 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 35 7000 No External cgy | |
| TCGA-CQ-7071 107 155 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CQ-7072 116 158 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-CQ-A4CD 156 204 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CQ-A4CH 120 148 Treatment Chemotherapy Cisplatin partial response No No | |
| TCGA-CQ-A4CH 119 163 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CQ-A4CI 118 163 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-CR-5243 16 72 Treatment Chemotherapy Carboplatin 9 340 mg 1 Other, Specify In Notes IV No | |
| TCGA-CR-5243 90 139 Treatment Chemotherapy Carboplatin 7 178 mg 2 Other, Specify In Notes IV No | |
| TCGA-CR-5243 91 139 Treatment Chemotherapy Paclitaxel 7 69 mg 2 Other, Specify In Notes IV No | |
| TCGA-CR-5243 16 72 Treatment Chemotherapy Paclitaxel 9 138 mg 1 Other, Specify In Notes IV No | |
| TCGA-CR-5243 90 139 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-5243 90 139 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-5247 19 80 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-5247 19 80 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-5247 21 71 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-5247 21 71 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-5247 21 71 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-5248 42 84 Treatment Chemotherapy Oxaliplatin No Yes | |
| TCGA-CR-5248 42 84 Treatment Chemotherapy Pemetrexed No Yes | |
| TCGA-CR-5248 137 179 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-5248 137 179 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-5248 1124 1152 Treatment Chemotherapy Bevacizumab clinical progressive disease No Yes | |
| TCGA-CR-5248 1124 1152 Treatment Chemotherapy Docetaxel clinical progressive disease No Yes | |
| TCGA-CR-5248 1124 1152 Treatment Chemotherapy Cisplatin clinical progressive disease No Yes | |
| TCGA-CR-5248 1194 1208 Treatment Immunotherapy Cixutumumab No Yes | |
| TCGA-CR-5248 137 183 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-5248 137 183 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-5249 102 140 Treatment Chemotherapy Cetuximab mg 1 Adjuvant IV No | |
| TCGA-CR-5249 107 140 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 30 6000 No External Beam cgy | |
| TCGA-CR-5249 107 140 Treatment Radiation Therapy Radiation 2 Adjuvant Regional Site 1 30 5700 No External Beam cgy | |
| TCGA-CR-5249 107 140 Treatment Radiation Therapy Radiation 3 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CR-5250 57 136 Treatment Chemotherapy Cisplatin 232 mg 1 Other, Specify In Notes IV No | |
| TCGA-CR-5250 56 113 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 30 5400 No External Beam cgy | |
| TCGA-CR-5250 56 113 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Primary Tumor Field 1 38 6840 No External Beam cgy | |
| TCGA-CR-6467 75 118 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 5400 No External Beam cgy | |
| TCGA-CR-6467 75 118 Treatment Radiation Therapy Radiation 2 Adjuvant Regional Site 1 30 6000 No External Beam cgy | |
| TCGA-CR-6470 85 113 Treatment Chemotherapy Paclitaxel 5 221 mg 1 Adjuvant IV No 1105 mg | |
| TCGA-CR-6470 85 113 Treatment Chemotherapy Carboplatin 5 70 mg 1 Adjuvant IV No 350 mg | |
| TCGA-CR-6470 79 115 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 27 5130 No External Beam cgy | |
| TCGA-CR-6470 79 115 Treatment Radiation Therapy Radiation 2 Adjuvant Regional Site 1 27 5400 No External Beam cgy | |
| TCGA-CR-6470 79 115 Treatment Radiation Therapy Radiation 3 Adjuvant Primary Tumor Field 1 27 5400 No External Beam cgy | |
| TCGA-CR-6471 1052 1052 Treatment Chemotherapy Cetuximab 1 400 mg/m2 3 Palliative IV No | |
| TCGA-CR-6471 548 595 Treatment Chemotherapy Paclitaxel 8 60 mg/m2 1 Recurrence IV No | |
| TCGA-CR-6471 618 646 Treatment Chemotherapy Carboplatin 5 1.5 auc 2 Recurrence IV No | |
| TCGA-CR-6471 1108 1129 Treatment Chemotherapy Docetaxel 4 40 mg/m2 5 Palliative IV No | |
| TCGA-CR-6471 548 595 Treatment Chemotherapy Carboplatin 8 2 auc 1 Recurrence IV No | |
| TCGA-CR-6471 618 646 Treatment Chemotherapy Paclitaxel 5 35 mg/m2 2 Recurrence IV No | |
| TCGA-CR-6471 1059 1087 Treatment Chemotherapy Methotrexate 5 30 mg/m2 4 Palliative IV No | |
| TCGA-CR-6471 77 114 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 27 5130 No External Beam cgy | |
| TCGA-CR-6471 614 646 Treatment Radiation Therapy Radiation 2 Recurrence Regional Site 2 50 6250 No External Beam cgy | |
| TCGA-CR-6471 77 114 Treatment Radiation Therapy Radiation 3 Adjuvant Primary Tumor Field 1 27 5400 No External Beam cgy | |
| TCGA-CR-6471 614 646 Treatment Radiation Therapy Radiation 4 Recurrence Primary Tumor Field 2 50 6250 No External Beam cgy | |
| TCGA-CR-6471 1081 1081 Treatment Radiation Therapy Radiation 5 Palliative Distant Recurrence 4 No Other cgy | |
| TCGA-CR-6471 77 114 Treatment Radiation Therapy Radiation 6 Adjuvant Regional Site 1 27 5400 No External Beam cgy | |
| TCGA-CR-6471 839 Treatment Radiation Therapy Radiation 7 Recurrence Regional Site 3 No External Beam cgy | |
| TCGA-CR-6472 109 123 Treatment Chemotherapy Carboplatin 3 1 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-6472 109 123 Treatment Chemotherapy Paclitaxel 3 30 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6472 28 84 Treatment Chemotherapy Paclitaxel 9 60 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6472 28 84 Treatment Chemotherapy Carboplatin 9 2 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6472 109 154 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-6472 109 154 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-6472 109 154 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-6473 47 94 Treatment Chemotherapy Paclitaxel 3 30 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6473 19 40 Treatment Chemotherapy Paclitaxel 4 60 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6473 19 40 Treatment Chemotherapy Carboplatin 4 2 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6473 47 94 Treatment Chemotherapy Carboplatin 2 1 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-6473 45 94 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-6473 45 94 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-6473 45 94 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-6474 108 150 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CR-6477 77 84 Treatment Chemotherapy Paclitaxel 2 30 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6477 10 66 Treatment Chemotherapy Carboplatin 8 2 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6477 10 66 Treatment Chemotherapy Paclitaxel 8 60 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6477 77 84 Treatment Chemotherapy Carboplatin 2 1 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-6477 78 123 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 32 6720 No External Beam cgy | |
| TCGA-CR-6477 78 123 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 24 5040 No External Beam cgy | |
| TCGA-CR-6477 78 123 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Primary Tumor Field 1 24 5040 No External Beam cgy | |
| TCGA-CR-6478 125 162 Treatment Chemotherapy Paclitaxel 5 30 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6478 125 162 Treatment Chemotherapy Carboplatin 5 1 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-6478 44 107 Treatment Chemotherapy Paclitaxel 9 60 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6478 44 107 Treatment Chemotherapy Carboplatin 9 2 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6478 125 178 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 27 5400 No External Beam cgy | |
| TCGA-CR-6478 125 178 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 3 1890 No External Beam cgy | |
| TCGA-CR-6478 125 178 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Primary Tumor Field 1 24 5040 No External Beam cgy | |
| TCGA-CR-6480 27 85 Treatment Chemotherapy Cisplatin 3 75 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6480 27 85 Treatment Chemotherapy Cetuximab 3 900 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6480 27 85 Treatment Chemotherapy Paclitaxel 3 270 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6480 103 145 Treatment Chemotherapy Cetuximab 7 250 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6480 103 152 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 27 5400 No External Beam cgy | |
| TCGA-CR-6480 103 152 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 27 5130 No External Beam cgy | |
| TCGA-CR-6480 103 152 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 35 7000 No External Beam cgy | |
| TCGA-CR-6481 31 73 Treatment Chemotherapy Paclitaxel 5 30 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6481 31 73 Treatment Chemotherapy Carboplatin 5 1 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6481 29 74 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-6481 29 74 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 24 5040 No External Beam cgy | |
| TCGA-CR-6481 29 74 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-6482 74 74 Treatment Chemotherapy Paclitaxel 1 90 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6482 158 193 Treatment Chemotherapy Paclitaxel 6 30 mg/m2 3 Other, Specify In Notes IV No | |
| TCGA-CR-6482 74 74 Treatment Chemotherapy Cetuximab 1 400 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6482 158 193 Treatment Chemotherapy Carboplatin 6 1 auc 3 Other, Specify In Notes IV No | |
| TCGA-CR-6482 88 137 Treatment Chemotherapy Paclitaxel 8 60 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-6482 74 74 Treatment Chemotherapy Cisplatin 1 75 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6482 88 137 Treatment Chemotherapy Carboplatin 8 2 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-6482 154 198 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-6482 154 198 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 24 5040 No External Beam cgy | |
| TCGA-CR-6482 154 198 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-6484 109 144 Treatment Chemotherapy Paclitaxel 6 30 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-6484 109 144 Treatment Chemotherapy Carboplatin 6 1 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-6484 109 154 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CR-6484 109 154 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 25 5000 No External Beam cgy | |
| TCGA-CR-6484 109 154 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 33 6600 No External Beam cgy | |
| TCGA-CR-6491 191 201 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-6491 191 201 Treatment Chemotherapy Docetaxel complete response No No | |
| TCGA-CR-6491 191 201 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field No External | |
| TCGA-CR-6492 114 145 Treatment Radiation Therapy Radiation 1 Adjuvant 1 No External Beam | |
| TCGA-CR-6493 100 150 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-6493 100 150 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-6493 100 150 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 7000 No External cgy | |
| TCGA-CR-7365 140 192 Treatment Chemotherapy 1 Adjuvant No | |
| TCGA-CR-7365 140 192 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No External Beam | |
| TCGA-CR-7367 90 98 Treatment Chemotherapy Paclitaxel No No | |
| TCGA-CR-7367 90 98 Treatment Chemotherapy Carboplatin No No | |
| TCGA-CR-7367 95 132 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 27 5130 No External Beam cgy | |
| TCGA-CR-7367 95 132 Treatment Radiation Therapy Radiation 2 Adjuvant Regional Site 1 27 5400 No External Beam cgy | |
| TCGA-CR-7367 95 132 Treatment Radiation Therapy Radiation 3 Adjuvant Primary Tumor Field 1 27 5400 No External Beam cgy | |
| TCGA-CR-7370 28 80 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 28 5400 No External Beam cgy | |
| TCGA-CR-7373 96 138 Treatment Chemotherapy Cisplatin 1 Adjuvant IV No | |
| TCGA-CR-7373 96 138 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No External Beam | |
| TCGA-CR-7379 126 162 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 25 5000 No External Beam cgy | |
| TCGA-CR-7379 126 169 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-CR-7380 92 153 Treatment Chemotherapy 1 Adjuvant IV No | |
| TCGA-CR-7380 100 150 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 33 6600 No External Beam cgy | |
| TCGA-CR-7380 100 140 Treatment Radiation Therapy Radiation 2 Adjuvant Primary Tumor Field 1 25 5000 No External Beam cgy | |
| TCGA-CR-7383 462 483 Treatment Chemotherapy Paclitaxel partial response No No | |
| TCGA-CR-7383 462 483 Treatment Chemotherapy Carboplatin partial response No No | |
| TCGA-CR-7385 29 87 Treatment Chemotherapy 1 Adjuvant IV No | |
| TCGA-CR-7385 29 87 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 No External Beam | |
| TCGA-CR-7386 97 132 Treatment Chemotherapy Paclitaxel 6 30 mg/m2 1 Adjuvant IV No | |
| TCGA-CR-7386 97 132 Treatment Chemotherapy Carboplatin 6 1 auc 1 Adjuvant IV No | |
| TCGA-CR-7386 96 135 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 29 5800 No External Beam cgy | |
| TCGA-CR-7386 96 135 Treatment Radiation Therapy Radiation 2 Adjuvant Regional Site 1 29 4390 No External Beam cgy | |
| TCGA-CR-7388 65 93 Treatment Chemotherapy Carboplatin 5 2 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-7388 114 121 Treatment Chemotherapy Paclitaxel 2 30 mg/m2 2 Other, Specify In Notes IV No | |
| TCGA-CR-7388 705 733 Treatment Chemotherapy Cetuximab 3 Palliative IV No | |
| TCGA-CR-7388 114 121 Treatment Chemotherapy Carboplatin 2 1 auc 2 Other, Specify In Notes IV No | |
| TCGA-CR-7388 65 93 Treatment Chemotherapy Paclitaxel 5 60 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-7388 110 148 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 21 3570 No External Beam cgy | |
| TCGA-CR-7388 110 148 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Primary Tumor Field 1 21 4410 No External Beam cgy | |
| TCGA-CR-7388 110 148 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Regional Site 1 21 4410 No External Beam cgy | |
| TCGA-CR-7389 31 73 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-7389 31 73 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-7389 31 75 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CR-7389 31 75 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-7389 31 75 Treatment Radiation Therapy Radiation 3 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-7390 134 176 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 21 6000 No External cgy | |
| TCGA-CR-7390 134 176 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External | |
| TCGA-CR-7392 109 151 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6000 No External | |
| TCGA-CR-7392 109 151 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5400 No External | |
| TCGA-CR-7393 -303 105 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-7393 63 105 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-7393 62 104 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field No External | |
| TCGA-CR-7394 106 126 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 15 3000 No External cgy | |
| TCGA-CR-7394 106 126 Treatment Radiation Therapy Radiation 2 complete response Regional Site 15 3000 No External cgy | |
| TCGA-CR-7397 63 99 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-7397 63 99 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-7397 61 100 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 27 4860 No External cgy | |
| TCGA-CR-7397 61 100 Treatment Radiation Therapy Radiation 2 complete response Regional Site 27 6000 No External cgy | |
| TCGA-CR-7397 61 100 Treatment Radiation Therapy Radiation 3 complete response Regional Site 27 4860 No External cgy | |
| TCGA-CR-7402 37 101 Treatment Chemotherapy Carboplatin 1.5 auc 1 Other, Specify In Notes IV No | |
| TCGA-CR-7402 37 101 Treatment Chemotherapy Paclitaxel 40 mg/m2 1 Other, Specify In Notes IV No | |
| TCGA-CR-7402 36 101 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 7020 No External Beam cgy | |
| TCGA-CR-7402 36 101 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 5040 No External Beam cgy | |
| TCGA-CR-7404 18 67 Treatment Chemotherapy Paclitaxel No No | |
| TCGA-CR-7404 1297 1318 Treatment Chemotherapy clinical progressive disease phase i trial No Yes | |
| TCGA-CR-7404 1332 1416 Treatment Chemotherapy Pemetrexed No No | |
| TCGA-CR-7404 18 67 Treatment Chemotherapy Carboplatin No No | |
| TCGA-CR-7404 85 135 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-CR-7404 85 135 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-CR-7404 298 354 Treatment Chemotherapy Cetuximab partial response No No | |
| TCGA-CR-7404 375 415 Treatment Chemotherapy Capecitabine No No | |
| TCGA-CR-7404 466 599 Treatment Chemotherapy Cetuximab No No | |
| TCGA-CR-7404 606 634 Treatment Chemotherapy Paclitaxel stable disease No No | |
| TCGA-CR-7404 1052 1080 Treatment Chemotherapy Methotrexate No No | |
| TCGA-CR-7404 78 137 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Primary Primary Tumor Field 1 33 6930 No External Beam cgy | |
| TCGA-CR-7404 78 137 Treatment Radiation Therapy Radiation 2 Other, Specify In Notes Primary Regional Site 1 33 5610 No External Beam cgy | |
| TCGA-CR-7404 78 137 Treatment Radiation Therapy Radiation 4 Other, Specify In Notes Primary Regional Site 1 33 6930 No External Beam cgy | |
| TCGA-CV-5430 1641 1702 Treatment Chemotherapy Carboplatin 4 Recurrence IV No | |
| TCGA-CV-5430 1641 1702 Treatment Chemotherapy Paclitaxel 4 Recurrence IV No | |
| TCGA-CV-5430 1641 1702 Treatment Chemotherapy Irinotecan 4 Recurrence IV No | |
| TCGA-CV-5430 379 382 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 4 50 No External Beam cgy | |
| TCGA-CV-5431 28 69 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 9 7000 No External Beam cgy | |
| TCGA-CV-5434 3246 3259 Treatment Chemotherapy Carboplatin 2 Recurrence IV No | |
| TCGA-CV-5434 3246 3259 Treatment Chemotherapy Paclitaxel 2 Recurrence IV No | |
| TCGA-CV-5434 45 87 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 6000 No External Beam cgy | |
| TCGA-CV-5435 28 63 Treatment Chemotherapy Carboplatin 2 Adjuvant IV No | |
| TCGA-CV-5435 305 336 Treatment Chemotherapy Paclitaxel Recurrence IV No | |
| TCGA-CV-5435 305 336 Treatment Chemotherapy Carboplatin Recurrence IV No | |
| TCGA-CV-5435 21 62 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 30 6000 No External Beam cgy | |
| TCGA-CV-5439 231 345 Treatment Chemotherapy Carboplatin 6 Recurrence IV No | |
| TCGA-CV-5439 378 440 Treatment Chemotherapy Gefitinib 2 Palliative PO No | |
| TCGA-CV-5439 64 108 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 33 4500 No External Beam cgy | |
| TCGA-CV-5440 19 Treatment Chemotherapy Paclitaxel Adjuvant IV Yes | |
| TCGA-CV-5440 28 86 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 30 60 No External Beam cgy | |
| TCGA-CV-5441 52 89 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 30 60 No External Beam | |
| TCGA-CV-5966 33 78 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 20 40 No External gy | |
| TCGA-CV-5966 33 78 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-5973 50 80 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-5977 40 82 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-5977 40 82 Treatment Radiation Therapy Radiation 2 complete response Regional Site 21 42 No External gy | |
| TCGA-CV-5979 43 84 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 30 6000 No External Beam cgy | |
| TCGA-CV-6936 73 134 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 30 66 No External gy | |
| TCGA-CV-6941 31 70 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 62 No External gy | |
| TCGA-CV-6941 31 70 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-6950 26 56 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 63 No External | |
| TCGA-CV-6954 48 89 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External | |
| TCGA-CV-6954 48 89 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External | |
| TCGA-CV-6959 140 160 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 15 45 No External gy | |
| TCGA-CV-7090 69 108 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 2 60 No External gy | |
| TCGA-CV-7090 69 108 Treatment Radiation Therapy Radiation 2 complete response Regional Site 2 50 No External gy | |
| TCGA-CV-7235 46 81 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 20 40 No External gy | |
| TCGA-CV-7235 43 81 Treatment Radiation Therapy Radiation 2 complete response Regional Site 10 20 No External gy | |
| TCGA-CV-7238 86 127 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-7250 28 84 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External | |
| TCGA-CV-7252 33 89 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 35 63 No External gy | |
| TCGA-CV-7416 334 334 Treatment Chemotherapy Cisplatin No No | |
| TCGA-CV-7416 0 Treatment Radiation Therapy Radiation 1 Other, Specify In Notes Neoadjuvant Primary Tumor Field External Beam | |
| TCGA-CV-7418 62 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-CV-7418 509 567 Treatment Radiation Therapy Radiation 2 Local Recurrence 31 60 No External gy | |
| TCGA-CV-7422 41 78 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 30 No External gy | |
| TCGA-CV-7422 41 78 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-7429 70 Treatment Radiation Therapy Radiation 1 partial response Primary Tumor Field 12 36 No External gy | |
| TCGA-CV-7435 43 87 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 30 No External gy | |
| TCGA-CV-7435 -291 87 Treatment Radiation Therapy Radiation 2 complete response Regional Site 27 54 No External gy | |
| TCGA-CV-7435 -291 87 Treatment Radiation Therapy Radiation 3 complete response Regional Site 14 42 No External gy | |
| TCGA-CV-A45R 39 78 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 31 62 No External gy | |
| TCGA-CV-A45R 39 78 Treatment Radiation Therapy Radiation 2 complete response Regional Site 13 39 No External gy | |
| TCGA-CV-A45U 31 70 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A45U 31 70 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-A45X 68 107 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A45X 68 107 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-A45Y 37 78 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A45Z 965 1004 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A460 28 69 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 21 42 No External gy | |
| TCGA-CV-A461 39 52 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A461 39 52 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 54 No External gy | |
| TCGA-CV-A464 70 108 Treatment Radiation Therapy Radiation 1 complete response Local Recurrence 30 60 No External gy | |
| TCGA-CV-A464 70 108 Treatment Radiation Therapy Radiation 2 complete response Local Recurrence 30 57 No External gy | |
| TCGA-CV-A464 70 108 Treatment Radiation Therapy Radiation 3 complete response Regional Site 30 54 No External gy | |
| TCGA-CV-A468 26 67 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 21 42 No External gy | |
| TCGA-CV-A468 26 67 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-A468 26 67 Treatment Radiation Therapy Radiation 3 complete response Regional Site 14 42 No External gy | |
| TCGA-CV-A6JD 41 80 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6JD 41 80 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External gy | |
| TCGA-CV-A6JN 39 77 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6JN 39 77 Treatment Radiation Therapy Radiation 2 complete response Regional Site 30 57 No External gy | |
| TCGA-CV-A6JO 28 69 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6JU 75 110 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6JU 75 110 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 50 No External | |
| TCGA-CV-A6JY 52 94 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6JY 52 94 Treatment Radiation Therapy Radiation 2 complete response Regional Site 30 56 No External gy | |
| TCGA-CV-A6K1 44 85 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-CV-A6K2 53 92 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 30 60 No External gy | |
| TCGA-D6-6515 65 71 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 5 2000 No External Beam cgy | |
| TCGA-D6-6517 194 257 Treatment Chemotherapy Methotrexate 8 8 mg Progression IV No 62.8 mg | |
| TCGA-D6-6517 270 331 Treatment Radiation Therapy Radiation 1 Palliative Distant Site 2000 No External Beam cgy | |
| TCGA-D6-6823 84 97 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 32 6200 No External Beam cgy | |
| TCGA-D6-6827 57 67 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 8 4800 No Implants cgy | |
| TCGA-D6-A6EK 39 105 Treatment Chemotherapy Cisplatin partial response No No | |
| TCGA-D6-A6EK 39 105 Treatment Radiation Therapy Radiation 1 partial response Primary Tumor Field 35 70 No External gy | |
| TCGA-D6-A6EM 51 94 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 66 No External gy | |
| TCGA-D6-A6EN 83 125 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-D6-A6EO 73 119 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 66 No External gy | |
| TCGA-D6-A6EQ 51 92 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-D6-A6ES 88 132 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-D6-A74Q 44 88 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-DQ-5624 36 63 Treatment Chemotherapy Cisplatin 2 80 mg/m2 1 Adjuvant IV No 347 mg | |
| TCGA-DQ-5624 37 86 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 5000 No External Beam cgy | |
| TCGA-DQ-5629 52 98 Treatment Chemotherapy Carboplatin 07 1 Adjuvant IV No 233 mg | |
| TCGA-DQ-5629 52 98 Treatment Radiation Therapy Radiation 1 Adjuvant Regional Site 1 35 7000 No External Beam cgy | |
| TCGA-DQ-5630 34 76 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 30 6000 No External Beam cgy | |
| TCGA-DQ-5631 32 67 Treatment Chemotherapy Cisplatin 5 40 mg/m2 01 Adjuvant IV No 80 mg | |
| TCGA-DQ-5631 475 518 Treatment Chemotherapy Carboplatin 02 2 Palliative IV No 577 mg | |
| TCGA-DQ-5631 475 518 Treatment Chemotherapy Pemetrexed 2 2 Palliative IV No 965 mg | |
| TCGA-DQ-5631 32 71 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6000 No External Beam cgy | |
| TCGA-DQ-5631 449 456 Treatment Radiation Therapy Radiation 2 Palliative Chest Distant Recurrence 2 5 2000 No External Beam cgy | |
| TCGA-DQ-5631 477 491 Treatment Radiation Therapy Radiation 3 Palliative Back Distant Recurrence 3 12 3600 No External Beam cgy | |
| TCGA-DQ-7588 159 215 Treatment Chemotherapy Cetuximab 1 1 Recurrence IV No | |
| TCGA-DQ-7588 379 421 Treatment Chemotherapy Docetaxel 3 152 mg 2 Palliative IV No 455 mg | |
| TCGA-DQ-7588 379 421 Treatment Chemotherapy Gossypol 3 80 mg/day 2 Palliative PO No 480 mg | |
| TCGA-DQ-7588 159 215 Treatment Chemotherapy Carboplatin 1 1 Recurrence IV No | |
| TCGA-DQ-7588 421 425 Treatment Chemotherapy Gossypol 1 20 mg/day 2 Palliative PO No 100 mg | |
| TCGA-DQ-7588 159 215 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 32 6400 No External Beam cgy | |
| TCGA-DQ-7589 9 34 Treatment Chemotherapy Carboplatin stable disease No No | |
| TCGA-DQ-7589 9 34 Treatment Chemotherapy Docetaxel stable disease No No | |
| TCGA-DQ-7589 9 34 Treatment Chemotherapy Fluorouracil stable disease No No | |
| TCGA-DQ-7589 119 154 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-DQ-7589 119 154 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-DQ-7589 119 164 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-DQ-7590 45 87 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-DQ-7590 45 87 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-DQ-7590 45 91 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 70 No External gy | |
| TCGA-DQ-7591 22 69 Treatment Chemotherapy Carboplatin 1 83 mg/wk 1 Adjuvant IV No 664 mg | |
| TCGA-DQ-7591 22 69 Treatment Chemotherapy Paclitaxel 1 56 mg/wk 1 Adjuvant IV No 448 mg | |
| TCGA-DQ-7591 22 70 Treatment Radiation Therapy Radiation 1 Adjuvant Concurrent Chemoradiation As Definitive Treatment Primary Tumor Field 1 35 7000 No External Beam cgy | |
| TCGA-DQ-7592 52 94 Treatment Chemotherapy Cisplatin 1 65 mg/wk 1 Adjuvant IV No 455 mg | |
| TCGA-DQ-7592 52 104 Treatment Radiation Therapy Radiation 1 Adjuvant Primary Tumor Field 1 6600 No External Beam cgy | |
| TCGA-DQ-7593 25 67 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-DQ-7593 25 67 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-DQ-7593 25 82 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 70 No External gy | |
| TCGA-DQ-7594 12 53 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-DQ-7594 12 53 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-DQ-7594 12 61 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 70 No External gy | |
| TCGA-DQ-7595 34 62 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-DQ-7595 34 85 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 70 No External gy | |
| TCGA-DQ-7596 13 60 Treatment Chemotherapy Cetuximab partial response No No | |
| TCGA-DQ-7596 203 266 Treatment Chemotherapy Pemetrexed complete response No No | |
| TCGA-DQ-7596 203 266 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-DQ-7596 19 69 Treatment Radiation Therapy Radiation 1 partial response Primary Tumor Field 35 70 No External gy | |
| TCGA-F7-7848 92 117 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 18 36 No External gy | |
| TCGA-F7-7848 142 162 Treatment Radiation Therapy Radiation 2 complete response Regional Site 14 28 No External gy | |
| TCGA-F7-A50G 43 72 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 40 80 No External gy | |
| TCGA-F7-A50J 70 114 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-F7-A50J 70 114 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-F7-A61S 20 73 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 2 98 No External gy | |
| TCGA-F7-A61S 230 255 Treatment Radiation Therapy Radiation 2 stable disease Regional Site 1 38 No External gy | |
| TCGA-F7-A623 19 67 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 23 46 No External gy | |
| TCGA-F7-A624 77 148 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-H7-7774 424 454 Treatment Radiation Therapy Radiation 1 No | |
| TCGA-H7-8501 76 137 Treatment Chemotherapy complete response No | |
| TCGA-H7-8501 76 137 Treatment Radiation Therapy Radiation 1 complete response No | |
| TCGA-H7-8502 77 108 Treatment Chemotherapy No | |
| TCGA-H7-8502 77 108 Treatment Radiation Therapy Radiation 1 No | |
| TCGA-H7-A6C4 74 Treatment Chemotherapy Cisplatin complete response No | |
| TCGA-H7-A6C4 74 113 Treatment Radiation Therapy Radiation 1 complete response 63 No External gy | |
| TCGA-H7-A6C5 65 112 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-H7-A76A 62 101 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 63 No External gy | |
| TCGA-H7-A76A 62 101 Treatment Radiation Therapy Radiation 2 complete response Regional Site 60 No External gy | |
| TCGA-H7-A76A 62 101 Treatment Radiation Therapy Radiation 3 complete response Regional Site 51 No External | |
| TCGA-HD-7229 35 85 Treatment Chemotherapy Carboplatin No No | |
| TCGA-HD-7229 35 85 Treatment Chemotherapy Paclitaxel No No | |
| TCGA-HD-7229 35 85 Treatment Chemotherapy Cetuximab No No | |
| TCGA-HD-7229 187 187 Treatment Chemotherapy Cisplatin clinical progressive disease No No | |
| TCGA-HD-7229 187 187 Treatment Chemotherapy Docetaxel clinical progressive disease No No | |
| TCGA-HD-7229 187 187 Treatment Chemotherapy Fluorouracil clinical progressive disease No No | |
| TCGA-HD-7229 35 85 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 35 7000 No External cgy | |
| TCGA-HD-7753 71 85 Treatment Chemotherapy Cetuximab complete response No No | |
| TCGA-HD-7753 68 126 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6630 No External cgy | |
| TCGA-HD-7831 72 116 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-HD-7832 126 172 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field No External | |
| TCGA-HD-8224 90 147 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-HD-8224 97 147 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 33 6600 No External cgy | |
| TCGA-HD-8314 79 121 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-HD-8314 79 114 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-HL-7533 24 87 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-HL-7533 24 87 Treatment Chemotherapy Docetaxel complete response No No | |
| TCGA-HL-7533 24 87 Treatment Chemotherapy Capecitabine complete response No No | |
| TCGA-IQ-7630 102 147 Treatment Chemotherapy Docetaxel complete response No No | |
| TCGA-IQ-7630 102 147 Treatment Targeted Molecular Therapy Cetuximab complete response No No | |
| TCGA-IQ-7630 102 147 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-IQ-7632 73 114 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-IQ-A61E 96 138 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-IQ-A61E 103 142 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 60 No External gy | |
| TCGA-IQ-A61G 130 168 Treatment Chemotherapy Cisplatin clinical progressive disease No No | |
| TCGA-IQ-A61G 131 168 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 30 60 No External gy | |
| TCGA-IQ-A61J 64 99 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-IQ-A61J 62 101 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 60 No External gy | |
| TCGA-IQ-A61K 108 108 Treatment Chemotherapy Cisplatin No No | |
| TCGA-IQ-A61K 112 138 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 44 No External gy | |
| TCGA-IQ-A61L 262 Treatment Chemotherapy Cisplatin Yes No | |
| TCGA-IQ-A61L 262 Treatment Chemotherapy Cetuximab Yes No | |
| TCGA-IQ-A61L 50 85 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 9 18 No External gy | |
| TCGA-IQ-A61L 254 262 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Local Recurrence 4 8 No External gy | |
| TCGA-IQ-A61O 69 111 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-IQ-A61O 69 127 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-IQ-A6SG 59 111 Treatment Radiation Therapy Radiation 1 Regional Site 30 60 No External gy | |
| TCGA-IQ-A6SH 50 95 Treatment Radiation Therapy Radiation 1 Regional Site 30 60 No External gy | |
| TCGA-KU-A66S 59 119 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 38 6840 No External cgy | |
| TCGA-KU-A66T 121 166 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 30 5400 No External cgy | |
| TCGA-KU-A6H7 65 100 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-KU-A6H7 65 115 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6660 No External cgy | |
| TCGA-KU-A6H7 65 115 Treatment Radiation Therapy Radiation 2 complete response Regional Site 33 6660 No External cgy | |
| TCGA-KU-A6H7 65 115 Treatment Radiation Therapy Radiation 3 complete response Regional Site 33 5610 No External cgy | |
| TCGA-KU-A6H7 65 115 Treatment Radiation Therapy Radiation 4 complete response Regional Site 33 5280 No External cgy | |
| TCGA-KU-A6H8 122 174 Treatment Immunotherapy Cetuximab clinical progressive disease No No | |
| TCGA-KU-A6H8 210 Treatment Chemotherapy Paclitaxel Yes No | |
| TCGA-KU-A6H8 210 Treatment Chemotherapy Carboplatin Yes No | |
| TCGA-KU-A6H8 116 172 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 36 7100 No External cgy | |
| TCGA-KU-A6H8 116 172 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Regional Site 36 5240 No External cgy | |
| TCGA-KU-A6H8 116 172 Treatment Radiation Therapy Radiation 3 radiographic progressive disease Regional Site 36 5860 No External cgy | |
| TCGA-KU-A6H8 116 172 Treatment Radiation Therapy Radiation 4 radiographic progressive disease Regional Site 36 5550 No External cgy | |
| TCGA-MT-A51W 70 100 Treatment Radiation Therapy Radiation 1 stable disease Primary Tumor Field No External | |
| TCGA-MT-A67G 72 112 Treatment Chemotherapy Cisplatin No No | |
| TCGA-MT-A67G 50 105 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 7 6000 No External cgy | |
| TCGA-MZ-A5BI 41 70 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-MZ-A5BI 40 86 Treatment Radiation Therapy Radiation 1 complete response Regional Site 33 69.96 No External gy | |
| TCGA-MZ-A5BI 40 86 Treatment Radiation Therapy Radiation 2 complete response Primary Tumor Field 33 69.96 No External gy | |
| TCGA-MZ-A6I9 57 99 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-MZ-A6I9 365 421 Treatment Targeted Molecular Therapy Rigosertib clinical progressive disease No Yes | |
| TCGA-MZ-A6I9 449 449 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-MZ-A6I9 449 449 Treatment Chemotherapy Docetaxel clinical progressive disease No No | |
| TCGA-MZ-A6I9 57 102 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 69.96 No External gy | |
| TCGA-MZ-A6I9 57 102 Treatment Radiation Therapy Radiation 2 complete response Regional Site 33 69.96 No External gy | |
| TCGA-MZ-A7D7 77 119 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-MZ-A7D7 526 Treatment Targeted Molecular Therapy Cetuximab Yes Yes | |
| TCGA-MZ-A7D7 526 Treatment Chemotherapy Eribulin Yes Yes | |
| TCGA-MZ-A7D7 77 126 Treatment Radiation Therapy Radiation 1 complete response Regional Site 33 66 No External gy | |
| TCGA-MZ-A7D7 77 126 Treatment Radiation Therapy Radiation 2 complete response Primary Tumor Field 33 66 No External gy | |
| TCGA-P3-A5Q5 69 120 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6600 No External cgy | |
| TCGA-P3-A5Q5 69 120 Treatment Radiation Therapy Radiation 2 complete response Regional Site 6600 No External cgy | |
| TCGA-P3-A5Q6 43 104 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-P3-A5Q6 43 104 Treatment Chemotherapy Cetuximab complete response No No | |
| TCGA-P3-A5Q6 49 98 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 4000 No External cgy | |
| TCGA-P3-A5Q6 49 98 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5000 No External cgy | |
| TCGA-P3-A5QE 38 80 Treatment Radiation Therapy Radiation 1 complete response Regional Site 5400 No External cgy | |
| TCGA-P3-A5QE 38 80 Treatment Radiation Therapy Radiation 2 complete response Primary Tumor Field 6000 No External cgy | |
| TCGA-P3-A5QF 57 88 Treatment Chemotherapy Cetuximab No No | |
| TCGA-P3-A5QF 50 105 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 6660 No External cgy | |
| TCGA-P3-A5QF 50 105 Treatment Radiation Therapy Radiation 2 Regional Site 6660 No External cgy | |
| TCGA-P3-A6SW 61 122 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6480 No External cgy | |
| TCGA-P3-A6SW 61 122 Treatment Radiation Therapy Radiation 2 complete response Regional Site 6480 No External cgy | |
| TCGA-P3-A6SX 61 91 Treatment Chemotherapy complete response No No | |
| TCGA-P3-A6SX 30 91 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 5940 No External cgy | |
| TCGA-P3-A6SX 30 91 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5040 No External cgy | |
| TCGA-P3-A6T0 59 120 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6000 No External cgy | |
| TCGA-P3-A6T2 30 91 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-P3-A6T2 30 91 Treatment Radiation Therapy Radiation 1 complete response No External | |
| TCGA-P3-A6T3 61 92 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-P3-A6T3 61 120 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6640 No External cgy | |
| TCGA-P3-A6T3 61 120 Treatment Radiation Therapy Radiation 2 complete response Regional Site 6640 No External cgy | |
| TCGA-P3-A6T6 273 365 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-P3-A6T6 273 365 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-P3-A6T6 30 61 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6600 No External cgy | |
| TCGA-P3-A6T6 30 61 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5000 No External cgy | |
| TCGA-P3-A6T7 91 122 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-P3-A6T7 91 122 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 6600 No External cgy | |
| TCGA-P3-A6T7 91 122 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5000 No External cgy | |
| TCGA-P3-A6T8 92 122 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-P3-A6T8 92 122 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 5000 No External cgy | |
| TCGA-P3-A6T8 92 122 Treatment Radiation Therapy Radiation 2 complete response Regional Site 5000 No External cgy | |
| TCGA-QK-A652 77 77 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 31 59.3 No External gy | |
| TCGA-QK-A6IF 17 63 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-QK-A6IF 17 63 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-QK-A6IF 16 63 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 70 No External gy | |
| TCGA-QK-A6IF 16 63 Treatment Radiation Therapy Radiation 2 complete response Regional Site 35 59.85 No External gy | |
| TCGA-QK-A6IF 16 63 Treatment Radiation Therapy Radiation 3 complete response Regional Site 35 53.9 No External gy | |
| TCGA-QK-A6IG 51 98 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-QK-A6IG 51 98 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-QK-A6IG 51 98 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 33 66 No External gy | |
| TCGA-QK-A6IG 51 98 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Regional Site 33 59.73 No External gy | |
| TCGA-QK-A6IG 51 98 Treatment Radiation Therapy Radiation 3 radiographic progressive disease Regional Site 33 53.79 No External gy | |
| TCGA-QK-A6IH 49 84 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-QK-A6IH 49 84 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-QK-A6IH 49 91 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 38 56 No External gy | |
| TCGA-QK-A6IH 49 91 Treatment Radiation Therapy Radiation 2 Regional Site 38 50.96 No External gy | |
| TCGA-QK-A6IH 49 91 Treatment Radiation Therapy Radiation 3 Regional Site 38 45.92 No External gy | |
| TCGA-QK-A6II 57 99 Treatment Chemotherapy Cisplatin No No | |
| TCGA-QK-A6II 183 183 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-QK-A6II 183 183 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-QK-A6II 183 183 Treatment Targeted Molecular Therapy Cetuximab clinical progressive disease No No | |
| TCGA-QK-A6II 57 112 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 24 66.7 No External gy | |
| TCGA-QK-A6II 57 112 Treatment Radiation Therapy Radiation 2 Regional Site 24 60.73 No External gy | |
| TCGA-QK-A6II 57 112 Treatment Radiation Therapy Radiation 3 Regional Site 24 54.76 No External gy | |
| TCGA-QK-A6VB 78 116 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-QK-A6VB 78 116 Treatment Radiation Therapy Radiation 2 complete response Regional Site 30 6000 No External cgy | |
| TCGA-QK-A6VC 49 66 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 14 28 No External gy | |
| TCGA-QK-A6VC 49 66 Treatment Radiation Therapy Radiation 2 Regional Site 14 25.5 No External gy | |
| TCGA-QK-A8Z7 105 166 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-QK-A8Z7 105 166 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-QK-A8Z7 101 151 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 70.29 No External gy | |
| TCGA-QK-A8Z7 101 151 Treatment Radiation Therapy Radiation 2 complete response Regional Site 70.29 No External gy | |
| TCGA-QK-A8Z7 101 151 Treatment Radiation Therapy Radiation 3 complete response Regional Site 70.29 No External gy | |
| TCGA-QK-A8Z8 157 157 Treatment Chemotherapy Docetaxel No No | |
| TCGA-QK-A8Z8 157 157 Treatment Chemotherapy Cisplatin No No | |
| TCGA-QK-A8Z8 157 157 Treatment Chemotherapy Fluorouracil No No | |
| TCGA-QK-A8Z9 50 102 Treatment Chemotherapy Carboplatin complete response No No | |
| TCGA-QK-A8Z9 50 102 Treatment Chemotherapy Paclitaxel complete response No No | |
| TCGA-QK-A8Z9 267 302 Treatment Chemotherapy Carboplatin No No | |
| TCGA-QK-A8Z9 267 302 Treatment Chemotherapy Paclitaxel No No | |
| TCGA-QK-A8Z9 49 99 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 60.06 No External gy | |
| TCGA-QK-A8Z9 49 99 Treatment Radiation Therapy Radiation 2 complete response Regional Site 33 66 No External gy | |
| TCGA-QK-A8Z9 49 99 Treatment Radiation Therapy Radiation 3 complete response Regional Site 33 56.1 No External gy | |
| TCGA-QK-A8Z9 268 310 Treatment Radiation Therapy Radiation 4 Distant Site 28 50.4 No External gy | |
| TCGA-QK-A8ZA 71 118 Treatment Chemotherapy Cisplatin No No | |
| TCGA-QK-A8ZA 71 135 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 35 70 No External gy | |
| TCGA-QK-A8ZA 71 135 Treatment Radiation Therapy Radiation 2 Regional Site 35 63 No External gy | |
| TCGA-QK-A8ZA 71 135 Treatment Radiation Therapy Radiation 3 Regional Site 35 56 No External gy | |
| TCGA-QK-A8ZB 45 95 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 60 No External gy | |
| TCGA-QK-A8ZB 45 95 Treatment Radiation Therapy Radiation 2 complete response Regional Site 30 55.82 No External gy | |
| TCGA-QK-A8ZB 45 95 Treatment Radiation Therapy Radiation 3 complete response Regional Site 30 55.82 No External gy | |
| TCGA-QK-AA3J 56 106 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 70 No External gy | |
| TCGA-QK-AA3J 56 106 Treatment Radiation Therapy Radiation 2 complete response Regional Site 35 54 No External gy | |
| TCGA-QK-AA3J 56 106 Treatment Radiation Therapy Radiation 3 complete response Regional Site 35 54 No External gy | |
| TCGA-QK-AA3K 120 145 Treatment Chemotherapy Cisplatin No No | |
| TCGA-QK-AA3K 48 145 Treatment Radiation Therapy Radiation 1 Primary Tumor Field 30 66 No External gy | |
| TCGA-QK-AA3K 48 145 Treatment Radiation Therapy Radiation 2 Regional Site 30 60 No External gy | |
| TCGA-QK-AA3K 48 145 Treatment Radiation Therapy Radiation 3 Regional Site 30 60 No External gy | |
| TCGA-RS-A6TO 41 41 Treatment Immunotherapy Cetuximab complete response No No | |
| TCGA-RS-A6TO 48 94 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 35 7000 No External cgy | |
| TCGA-T2-A6WX 71 92 Treatment Chemotherapy Carboplatin clinical progressive disease No No | |
| TCGA-T2-A6WX 71 92 Treatment Chemotherapy Paclitaxel clinical progressive disease No No | |
| TCGA-T2-A6WX 71 92 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-T2-A6WX 71 128 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Primary Tumor Field 33 6996 No External cgy | |
| TCGA-T2-A6WX 71 128 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Regional Site No External | |
| TCGA-T2-A6WZ 247 303 Treatment Targeted Molecular Therapy Sonolisib stable disease pi3k inhibitor No Yes | |
| TCGA-T2-A6WZ 247 303 Treatment Chemotherapy Docetaxel stable disease No Yes | |
| TCGA-T2-A6WZ 128 163 Treatment Chemotherapy Cetuximab clinical progressive disease No No | |
| TCGA-T2-A6WZ 139 170 Treatment Radiation Therapy Radiation 1 radiographic progressive disease Regional Site 6000 No External cgy | |
| TCGA-T2-A6WZ 139 170 Treatment Radiation Therapy Radiation 2 radiographic progressive disease Primary Tumor Field 6000 No External cgy | |
| TCGA-T2-A6X0 60 95 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-T2-A6X0 63 99 Treatment Radiation Therapy Radiation 1 complete response Regional Site 66 No External gy | |
| TCGA-T2-A6X0 63 99 Treatment Radiation Therapy Radiation 2 complete response Primary Tumor Field 66 No External gy | |
| TCGA-TN-A7HI 66 117 Treatment Radiation Therapy Radiation 1 complete response 37 6600 No External cgy | |
| TCGA-TN-A7HJ 31 92 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-TN-A7HJ 43 98 Treatment Radiation Therapy Radiation 1 complete response Regional Site 33 6600 No External cgy | |
| TCGA-TN-A7HL 35 62 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-TN-A7HL 35 77 Treatment Radiation Therapy Radiation 1 complete response 30 6000 No External cgy | |
| TCGA-UF-A71B 212 269 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 32 6400 No External cgy | |
| TCGA-UF-A71B 212 269 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A71D 155 211 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A71D 155 203 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A71E 229 276 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A71E 229 266 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7J9 172 222 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A7J9 172 215 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JA 281 347 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 34 6120 No External cgy | |
| TCGA-UF-A7JA 281 338 Treatment Radiation Therapy Radiation 2 complete response Regional Site 28 5040 No External cgy | |
| TCGA-UF-A7JC 131 173 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-UF-A7JC 132 173 Treatment Radiation Therapy Radiation 1 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JC 132 187 Treatment Radiation Therapy Radiation 2 complete response Primary Tumor Field 33 6400 No External cgy | |
| TCGA-UF-A7JD 224 280 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-UF-A7JD 224 265 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JF 71 86 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-UF-A7JF 56 125 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 33 6600 No External cgy | |
| TCGA-UF-A7JF 56 111 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JH 102 151 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A7JH 102 140 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JJ 60 102 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-UF-A7JJ 59 107 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A7JJ 59 100 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JK 132 174 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-UF-A7JK 127 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 32 6400 No External cgy | |
| TCGA-UF-A7JK 127 181 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5600 No External cgy | |
| TCGA-UF-A7JO 214 265 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 34 6120 No External cgy | |
| TCGA-UF-A7JO 214 250 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 4500 No External cgy | |
| TCGA-UF-A7JS 95 144 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 30 6000 No External cgy | |
| TCGA-UF-A7JS 95 134 Treatment Radiation Therapy Radiation 2 complete response Regional Site 25 5000 No External cgy | |
| TCGA-UF-A7JT 173 229 Treatment Chemotherapy Cisplatin complete response No No | |
| TCGA-UF-A7JT 176 229 Treatment Radiation Therapy Radiation 1 complete response Primary Tumor Field 34 6120 No External cgy | |
| TCGA-UF-A7JT 176 221 Treatment Radiation Therapy Radiation 2 complete response Regional Site 28 5040 No External cgy | |
| TCGA-UP-A6WW 61 123 Treatment Radiation Therapy Radiation 1 partial response Primary Tumor Field 33 66 No External gy | |